I
93.35
10.79 (13.07%)
| 前收盘价格 | 82.56 |
| 收盘价格 | 86.76 |
| 成交量 | 1,809,828 |
| 平均成交量 (3个月) | 564,659 |
| 市值 | 9,896,686,592 |
| 预期市盈率 (P/E Forward) | 238.10 |
| 价格/销量 (P/S) | 15.59 |
| 股市价格/股市净资产 (P/B) | 8.79 |
| 52周波幅 | |
| 利润日期 | 20 Feb 2025 - 24 Feb 2025 |
| 营业毛利率 | -14.07% |
| 营业利益率 (TTM) | -22.15% |
| 稀释每股收益 (EPS TTM) | -0.870 |
| 季度收入增长率 (YOY) | 39.00% |
| 总债务/股东权益 (D/E MRQ) | 1.55% |
| 流动比率 (MRQ) | 7.66 |
| 营业现金流 (OCF TTM) | -62.16 M |
| 杠杆自由现金流 (LFCF TTM) | -6.95 M |
| 资产报酬率 (ROA TTM) | -7.45% |
| 股东权益报酬率 (ROE TTM) | -9.90% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Drug Manufacturers - Specialty & Generic (US) | 混合的 | 混合的 |
| Drug Manufacturers - Specialty & Generic (全球的) | 混合的 | 混合的 | |
| 股票 | Intra-Cellular Therapies Inc. | 看涨 | 看涨 |
AIStockmoo 评分
0.4
| 分析师共识 | 1.5 |
| 内部交易活动 | 1.5 |
| 价格波动 | -3.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 2.0 |
| 平均 | 0.40 |
|
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders. |
|
| 部门 | Healthcare |
| 行业 | Drug Manufacturers - Specialty & Generic |
| 投资方式 | Small Growth |
| 内部持股比例 | 2.33% |
| 机构持股比例 | 96.14% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 100.00 (Needham, 7.12%) | 保留 |
| 中 | 94.50 (1.23%) | |
| 低 | 89.00 (JP Morgan, -4.66%) | 购买 |
| 平均值 | 94.50 (1.23%) | |
| 总计 | 1 购买, 1 保留 | |
| 平均价格@调整类型 | 90.52 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Needham | 13 Jan 2025 | 100.00 (7.12%) | 保留 | 94.87 |
| 31 Oct 2024 | 100.00 (7.12%) | 购买 | 84.75 | |
| JP Morgan | 04 Nov 2024 | 89.00 (-4.66%) | 购买 | 86.17 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合